drugset / Trial / NCT00870727
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Phase 3
Completed
33 enrolled
Indiana University
Bristol-Myers Squibb · collabNational Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment with individuals with Pervasive Developmental Disorder. This is a double-blind, placebo-controlled study of aripiprazole in the management of the maladaptive behaviors of Pervasive Developmental Disorder. The investigators hypothesize that aripiprazole will be more effective than placebo for reducing aggression, tantrum and self-injurious behavior in children with Pervasive Developmental Disorder.
Timeline
- Start
- 2009-02
- Primary completion
- 2015-03
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 2 mg | Oral |
| Subject | Aripiprazole | Other / unclassified | 20 mg | Oral |